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Objectives. This multicenter study compared the efficacy and
safety of ibutilide versus procainamide for conversion of recent-
onset atrial flutter or fibrillation.
Background. Ibutilide fumarate is an intravenous (IV) class III
antiarrhythmic agent that has been shown to be significantly more
effective than placebo in the pharmacologic conversion of atrial
flutter and fibrillation to sinus rhythm. Procainamide is com-
monly used for conversion of recent-onset atrial fibrillation to
normal sinus rhythm.
Methods. One hundred twenty-seven patients (age range 22 to
92 years) with atrial flutter or fibrillation of 3 h to 90 days’ (mean
21 days) duration were randomized to receive either two 10-min IV
infusions of 1 mg of ibutilide fumarate, separated by a 10-min
infusion of 5% dextrose in sterile water, or three successive 10-min
IV infusions of 400 mg of procainamide hydrochloride.
Results. Of the 127 patients, 120 were evaluated for efficacy: 35
(58.3%) of 60 in the ibutilide group compared with 11 (18.3%) of
60 in the procainamide group had successful termination within
1.5 h of treatment (p < 0.0001). Seven patients were found to have
violated the protocol and were not included in the final evaluation.
In the patients with atrial flutter, ibutilide had a significantly
higher success rate than procainamide (76% [13 of 17] vs. 14% [3
of 22], p 5 0.001). Similarly, in the atrial fibrillation group,
ibutilide had a significantly higher success rate than procain-
amide (51% [22 of 43] vs. 21% [8 of 38], p 5 0.005). One patient
who received ibutilide, which was found to be a protocol violation,
had sustained polymorphic ventricular tachycardia requiring
direct current cardioversion. Seven patients who received procain-
amide became hypotensive.
Conclusions. This study establishes the superior efficacy of
ibutilide over procainamide when administered to patients to
convert either atrial fibrillation or atrial flutter to sinus rhythm.
Hypotension was the major adverse effect seen with procainamide.
A low incidence of serious proarrhythmia was seen with the
administration of ibutilide occurring at the end of infusion.
(J Am Coll Cardiol 1998;31:1414–9)
©1998 by the American College of Cardiology
Ibutilide fumarate is a selective intravenous (IV) class III
antiarrhythmic agent recently approved for the treatment of
atrial fibrillation and flutter. Previous studies with ibutilide
showed that it is significantly more effective than placebo in the
pharmacologic conversion of atrial flutter and fibrillation to
sinus rhythm (1,2). Ventricular proarrhythmia, a concern with
any antiarrhythmic agent, may occur during the use of ibutilide
(3,4).
Procainamide has not been approved in the United States
for use in atrial fibrillation or flutter; however, its use has been
found to be safe and effective in converting recent-onset atrial
fibrillation to normal sinus rhythm after IV doses ranging from
300 to 1,200 mg (5–7). The purpose of this study was to
compare the safety and efficacy of intravenous ibutilide fuma-
rate with intravenous procainamide for the termination of
recent-onset atrial flutter or fibrillation.
Methods
This multicenter study used a double-blind, randomized,
parallel-group, active-control, repeated-dose design in which
patients were stratified according to presenting arrhythmia
(atrial flutter or fibrillation) and duration of arrhythmia (24 h
or .24 h). Patients were randomized to receive either ibutilide
or procainamide. Patients in the ibutilide group received up to
two 10-min IV infusions of 1 mg of ibutilide, separated by a
10-min infusion of 5% dextrose in sterile water. Patients in the
procainamide group received up to three 10-min IV infusions
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of 400 mg of procainamide. The infusion was discontinued at
the time of arrhythmia termination or an adverse event.
Patients. Patients enrolled were .18 years of age, had
body weights .132 lb and ,300 lb and had no previous
exposure to ibutilide. Enrollment into the study was limited to
six men for every four women enrolled at each site, with the
exception of participating Veterans Affairs Medical Centers.
Female patients were surgically sterile or postmenopausal. All
patients had sustained atrial flutter or fibrillation persisting for
at least 3 h and ,90 days. If atrial fibrillation was present for
.3 days, patients received the appropriate anticoagulation
therapy before receiving study medication, unless transesoph-
ageal echocardiography confirmed that no atrial clot was
present. Patients considered for entry had corrected QT
intervals (QTc) #440 ms on a 12-lead electrocardiogram
(ECG), were hemodynamically stable (ventricular heart rate
$60 beats/min, systolic blood pressure $90 mm Hg, diastolic
blood pressure $60 mm Hg) and were without symptoms of
unstable angina or congestive heart failure. There were no
specific inclusion or exclusion criteria for patients who may
have recently had coronary artery bypass graft procedures. All
patients were required to have had serum sodium and magne-
sium levels within the normal range, serum potassium levels
$4.0 mEq/liter, liver function tests ,2 times the upper limit of
normal values and serum creatinine levels #2.0 mg/ml. Pa-
tients were excluded if they had histories of myocardial infarc-
tion within the previous 30 days, torsade de pointes, second- or
third-degree heart block, congestive heart failure (New York
Heart Association class III or higher) or any serious medical
condition that could interfere with the conduct or interpreta-
tion of the study results. Human subjects’ approval was ob-
tained by each site, and written informed consent was obtained
from each patient. On enrollment, a patient was randomized
into one of the two treatment groups.
Concurrent participation in another drug study or receipt of
an investigational drug within 30 days of the infusion was not
permitted. Atrioventricular (AV) node blockers, including
calcium-channel blockers, beta-blockers and digoxin, were
permitted for rate control. Class I or III antiarrhythmic
medications were discontinued at least five half-lives before
infusion of the study medication. Patients taking amiodarone
were excluded. Administration of additional antiarrhythmic
medication was delayed until 6 h after the end of the infusions
if the arrhythmia was not successfully terminated by the study
medication or if a malignant ventricular arrhythmia developed.
If the arrhythmia was terminated successfully by the study
medication, additional antiarrhythmic medication was delayed
until at least 24 h after the start of infusion. Other noninves-
tigational medications were limited to those essential to the
patient’s care.
The infusion was terminated on conversion of the arrhyth-
mia. It was also terminated if there was any change in rhythm
or AV conduction that was not hemodynamically tolerated or,
in the opinion of the investigator, that was threatening (or
potentially threatening) the patient’s safety. Such changes
included new bundle branch block, .50% increase in QRS
duration, QTc interval .600 ms, a new or repetitive form of
ventricular premature depolarization or hypotension (a de-
crease in systolic blood pressure .20 mm Hg or to a level
,80 mm Hg). Intravenous fluids could be administered to
increase the blood pressure.
Study procedures. The baseline period was defined as the
10 min before the beginning of the first infusion (210 to
0 min). Data collected during the baseline period included
laboratory evaluations, blood pressure and heart rate, a 12-
lead ECG and continuous ECG monitoring beginning at 210
minutes. Patients in atrial flutter or fibrillation at the end of the
baseline period proceeded to the treatment phase of the
protocol. The infusion period lasted from the beginning of the
first infusion (0 min) to the end of the third infusion (30 min).
During the infusion period, blood pressure and heart rate were
recorded every 5 min, and the patient’s rhythm was continu-
ously monitored. A 12-lead ECG was obtained at 30 min and
at the time of conversion or on development of a significant
rhythm change. The study medication was infused according to
schedule until atrial flutter or fibrillation was converted or a
medical event occurred that necessitated termination of treat-
ment. Pacing or direct current cardioversion was permitted if
the patient experienced a significant adverse rhythm change,
remained in atrial flutter or fibrillation past 90 min or reverted
to atrial flutter or fibrillation after initial successful conversion.
The postinfusion period lasted from the end of the infusion
period (30 min) to 24 h. A 12-lead ECG was obtained at the
time of arrhythmia conversion, on the appearance of a signif-
icant rhythm change during the 1-h period after the infusions,
at 90 min for patients whose arrhythmia had not yet terminated
and on the appearance of a significant adverse rhythm change
occurring from 90 min through 24 h. One-lead ECG monitor-
ing was continued for 24 h. Vital signs were recorded at 35 and
40 min and at 1, 1.5, 2, 4, 6, 8, 16 and 24 h after the start of the
first infusion. Blood and urine specimens for laboratory assays
were obtained at 24 h.
Safety evaluations. Safety of the study infusions was eval-
uated by calculating the mean change from baseline for systolic
and diastolic blood pressures and pulse rate, plus any signifi-
cant changes from baseline in the 12-lead ECG. Adverse
medical events and their relation to the study drug were noted
or volunteered by the patients during the 72 h after infusion,
and events were graded as mild, moderate or severe per the
patient. Patients who left the hospital were contacted by
telephone to obtain follow-up information through 72 h. All
adverse events were followed until they resolved. A serious
medical event was defined as that requiring hospital admission
Abbreviations and Acronyms
AV 5 atrioventricular
IV 5 intravenous
ECG 5 electrocardiogram, electrocardiographic
QTc 5 corrected QT interval
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or prolonging the hospital stay, requiring intervention to
prevent permanent incapacity or damage, producing significant
disability, immediately threatening the patient’s life or result-
ing in death.
Statistical methods. Comparability of treatment groups
with respect to age, height, weight and duration of arrhythmia
was assessed using the Scheffe´ F test derived from one-way
analysis of variance. Gender and history of cardiovascular
disease were examined for comparability of treatment groups,
using the chi-square test for two-way contingency tables. In
addition, efficacy—the proportion of patients converting—was
compared using the chi-square test for two-way contingency
tables. The efficacy analyses were conducted for patients with
atrial flutter and fibrillation (as determined by baseline ECGs)
both separately and combined.
For pulse rate and systolic and diastolic blood pressure,
assessment of the significance of the mean change from
baseline to each follow-up reading was made within treatment
groups using paired t tests. Comparisons between treatment
groups were made using the mean change from baseline and
the Scheffe´ F test derived from the usual one-way analysis of
variance fixed-effects model. The proportion of medical events
was assessed using the chi-square test for two-way contingency
tables. Statistical findings were deemed significant at p # 0.05.
Results
Comparability of treatment groups. The study enrolled
127 patients, but only 120 were evaluated for efficacy. All
patients were evaluated for safety of the drugs. Seven patients
were found to have violated the protocol and were not
included in the final evaluation. There were 60 patients in each
group whose data were evaluated. There were fewer patients
with atrial flutter (33%) than with atrial fibrillation (67%), and
the two drug groups were comparable in this regard. The two
groups were also comparable with respect to age, height,
weight, gender and cardiovascular disease history, as well as
duration of arrhythmias (Table 1). A broad spectrum of other
cardiovascular medications was in use in the 7 days before
infusion, and the two treatment groups were comparable in
this regard, as well.
Conversion rates. Conversion rates of atrial fibrillation or
flutter were higher in the ibutilide group (58%) than in the
procainamide group (18%) (p , 0.0001); this was true for both
atrial flutter (76% vs. 14%, p 5 0.0001) and atrial fibrillation
(51% vs. 21%, p 5 0.005) (Fig. 1). Patients who converted did
so in a mean of 31.2 min with ibutilide and 34.4 min with
procainamide. The analysis of variance for successes versus
failures indicated no differences in prolongation of the QTc
interval at 90 min between successes and failures in the
ibutilide group or the procainamide group.
Safety evaluations. Adverse events were generally more
common in the procainamide-treated group (46.2%) than in
the ibutilide-treated group (29.0%, p 5 0.047). Headache
(10.8%), hypotension (10.8%), flushing (3.1%), dizziness
(3.1%) and hypesthesia (3.1%) occurred in the procainamide
group but not in the ibutilide group. Extrasystole (4.8%)
occurred in the ibutilide group but not in the procainamide
group. Figure 2 illustrates the mean change in blood pressure
and pulse rate for all patients receiving either ibutilide or
procainamide. In the procainamide-treated group, there was a
statistically significant decrease from baseline in mean systolic
and mean diastolic blood pressure beginning at the start of
infusion and lasting through 24 h, except for mean diastolic
blood pressure at 1.5 and 2 h; this was not evident in the
ibutilide-treated group, except at 4, 6 and 16 h for mean
systolic blood pressure and 2 through 24 h for mean diastolic
blood pressure. The decrease in mean systolic and mean
diastolic pressure seen in the procainamide group corre-
sponded in time to the period of infusion of procainamide.
Blood pressure began to drop immediately after administra-
tion, and a maximal decrease in mean systolic blood pressure
was noted at 30 and 35 min. This differed from the ibutilide
Table 1. Patient Characteristics*
Characteristics
Ibutilide
Group
(n 5 60)
Procainamide
Group
(n 5 60)
Age (years) 64.3 67.7
Height (in.) 68.6 67.9
Weight (lb) 197.1 189.0
Gender (%)
Male 75.0 70.0
Female 25.0 30.0
Cardiovascular history
Coronary artery disease 38.3 53.3
Myocardial disease 18.3 15.0
Valvular disease 23.3 25.0
Arrhythmia 65.0 58.3
Other (hypertension,
hypercholesterolemia
and peripheral vascular disease)
66.1 60.0
Duration of arrhythmia (days) 22.3 6 24.7 17.0 6 23.0
Median 9.4 4.6
Range 0.2–84.5 0.2–89.5
*p 5 NS for all comparisons. Data presented are mean value 6SD, unless
otherwise indicated.
Figure 1. Rate of successful conversion of atrial fibrillation and flutter
in the ibutilide and procainamide groups. *p , 0.0001. **p 5 0.0001.
***p 5 0.005.
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group, whose mean blood pressure remained steady through
1.5 h. There was a statistically significant difference between
the treatment groups in both mean systolic and mean diastolic
blood pressure until 1.5 h. Severe hypotension occurred in
seven patients treated with procainamide, with decreases in
diastolic blood pressure up to 67 mm Hg, and three patients
necessitated discontinuation of infusion. In six of seven pa-
tients, the hypotension was classified by investigators as being
moderate or severe in intensity. Intervention with IV fluids or
dopamine, or both, was necessary for three patients, and in one
patient, blood pressure was unrecordable until after IV fluid
replacement. All but one of these events occurred during or
immediately after the infusion of procainamide. There was a
steady and statistically significant decrease in mean heart rate
in the ibutilide group through 24 h, whereas there was a
statistically significant increase in mean heart rate in the
procainamide group at 25 min, and then a statistically signifi-
cant decrease from 6 through 24 h. Although there was a
statistically significant difference in mean heart rate between
the treatment groups throughout the 24-h period, the magni-
tude of change within each group or between groups was not
clinically significant.
Three patients discontinued ibutilide because of adverse
events (one each for extrasystole, nonsustained monomorphic
ventricular tachycardia and QT interval prolongation). Four
patients discontinued procainamide for medical events (three
for hypotension [i.e., a decrease in systolic blood pressure
.20 mm Hg or to a level ,80 mm Hg] and one catheter site
reaction). Three medical events in the ibutilide group were
reported as serious. One patient developed sustained polymor-
phic ventricular tachycardia after 30 min of ibutilide infusion.
Electrical cardioversion was successful with a single applica-
tion of 200 J, and the patient alternated between atrial
fibrillation and normal sinus rhythm for the remainder of the
24-h observation period. It was determined that the patient was
in violation of the protocol, because the patient’s predose
serum magnesium level was 1.7 mg/dl and potassium level 3.8
mEq/liter, and the patient is therefore not included in the
group that was evaluable.
There were two other serious medical events: presyncope in
an 80-year old patient who felt presyncopal while standing at
23 h. He was in normal sinus rhythm with no orthostatic
changes. The patient never lost consciousness. This patient had
a history of hypertension, hypercholesterolemia, peripheral
vascular disease with angioplasty of the left iliac artery and
pacemaker placement in 1991 for bradycardia. These underly-
ing conditions are all risk factors for presyncope. The investi-
gator reporting the medical event did not believe the event was
related to exposure to ibutilide. Another patient who had a
history of multiple infarct dementia experienced acute delir-
ium at 8 h. The patient required sedation and safety restraints.
The patient had multiple sclerosis. The event was regarded by
the investigator as unrelated to exposure to ibutilide. Both
patients required prolongation of their hospital stay.
Discussion
This comparison study of intravenous ibutilide versus pro-
cainamide establishes that ibutilide is significantly more effec-
tive than procainamide (58% vs. 18%) in the acute conversion
of patients with atrial fibrillation and atrial flutter of up to 90
days’ duration. Although the number of patients with atrial
flutter was small, ibutilide was superior to procainamide in
converting this rhythm (76% vs. 14%). For the larger number
of patients with atrial fibrillation, ibutilide was also more
effective than procainamide (51% vs. 21%). A low incidence of
major proarrhythmia was the main adverse event seen with
administration of ibutilide, whereas hypotension was caused by
infusion of intravenous procainamide.
Previous studies. Previous studies using ibutilide to con-
vert atrial fibrillation have shown that ibutilide was effective in
the rapid conversion of new-onset atrial fibrillation with a
duration up to 37 days (1,2).
Figure 2. Mean change from baseline in systolic and diastolic blood
pressure and in pulse rate in ibutilide- and procainamide-treated
patients.
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Previous studies using procainamide for the rapid termina-
tion of atrial fibrillation demonstrated that IV procainamide
was highly effective (5–7). However, these studies had small
numbers of subjects and were largely uncontrolled, using
patients with atrial fibrillation of short duration, in some cases
,24 h. An extensive review of these studies, recently summa-
rized by Ellenbogen et al. (1) showed that procainamide was
much more successful if the duration of the atrial fibrillation
was ,7 days, especially ,24 h. The success of conversion was
markedly lower in patients with atrial fibrillation lasting .10
days.
In the present study, the mean durations of atrial fibrillation
and atrial flutter were 22 days for the ibutilide group and 17
days for the procainamide group. This longer duration of
arrhythmia may account for the lower efficacy of procainamide
in this study compared with the efficacy previously reported in
the published data.
Although other class III antiarrhythmic agents act on
potassium channels, ibutilide delays repolarization by the
activation of a slow, inward, predominantly sodium current
that increases the duration of the action potential. Further-
more, in animal studies, ibutilide has been shown to prolong
not only action potential duration, but also the atrial effective
refractory period. In these studies, ibutilide was found to be
significantly more potent than sotalol and encainide (8–14).
Procainamide, when administered by the oral route, affects
two phases of the cardiac action potential, because the metab-
olite produced by hepatic metabolism, N-acetylprocainamide,
has class III effects. Thus, when given by this route, procain-
amide blocks both fast sodium channels and transient outward
potassium channels. However, when given intravenously, pro-
cainamide acts mostly on conduction velocity, not on the
refractory period, and this was evidenced by the lack of QT
prolongation in patients who received procainamide in this
study.
As such, prolongation of the effective refractory period
would seem to be a determining factor in the increased efficacy
of ibutilide over procainamide seen in this study.
Clinical significance. The current anticoagulation guide-
lines recommend a minimum of 3 weeks of anticoagulation in
patients with atrial fibrillation lasting 48 h (15). This anticoag-
ulation period prolongs the duration in which the patient is in
atrial fibrillation. In patients in whom pharmacologic conver-
sion is chosen over electrical cardioversion as an initial ther-
apy, ibutilide may be a better alternative than procainamide
because it is more effective in atrial fibrillation of both short
and longer duration, as demonstrated in this study, whereas IV
procainamide has been shown to have efficacy only in atrial
fibrillation of very short duration.
Adverse effects. There were no deaths in the study and only
three serious medical events. Medical events such as ventric-
ular extrasystoles, QT prolongation and polymorphic ventric-
ular tachycardia have all been observed to occur with the
administration of ibutilide in previous studies (1–3). In the
present study, proarrhythmia was also seen with the adminis-
tration of ibutilide. The major proarrhythmic effect of ibutilide
was observed within 30 min of the start of infusion of ibutilide.
It was found that the one patient who developed sustained
polymorphic ventricular tachycardia had lower than acceptable
levels of potassium and magnesium. Although IV procain-
amide did not cause proarrhythmia, its hypotensive effects may
limit its use in certain patients.
The lower incidence of proarrhythmia in this study com-
pared with the dose-response study (1) may be due to stricter
inclusion and exclusion criteria than in previous studies using
ibutilide. In the dose-response study of ibutilide, all the
patients who had proarrhythmia had decreased left ventricular
function, one with class III congestive heart failure (1). This
comparison study did not specifically address ventricular func-
tion by echocardiography, and therefore no conclusion can be
made regarding the effects of left ventricular dysfunction on
the adverse effects found in this study. The occurrence of one
episode (1.6%) of sustained polymorphic ventricular tachycar-
dia is comparable with the overall incidence of 1.7% (10 of 586
patients) observed in a pooled sample of ibutilide-treated
patients from previous studies (4).
Conclusions. This study establishes the superior efficacy of
ibutilide over procainamide when administered to patients to
convert either atrial fibrillation or flutter. Hypotension was the
major adverse effect seen with procainamide. A low incidence
of serious proarrhythmia was seen with the administration of
ibutilide occurring at the end of infusion.
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MD; Highline Community Hospital, Seattle, Washington: Bert Green, MD;
Hahnemann University Hospital, Philadelphia, Pennsylvania: Scott Hessen,
MD; University of California at Davis Medical Center, Sacramento, California:
William R. Lewis, MD; Lankenau Hospital, Wynnewood, Pennsylvania: Peter
Kowey, MD; Shelby Medical Center, Birmingham, Alabama: Michael McKin-
ney, MD; Loyola University Medical Center, Maywood, Illinois: Brian Olshan-
sky, MD; Providence Medical Center, Portland, Oregon: Ronald Petersen, MD;
Memphis Veteran’s Medical Center, Memphis, Tennessee: John Riddle, MD;
Louisiana State University Medical Center, New Orleans, Louisiana: Gary
Sander, MD; McGuire Veterans Medical Center, Richmond, Virginia: Bruce
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